Advertisement

Hypogonadism: Treatment

  • John P. Mulhall
  • Peter J. Stahl
  • Doron S. Stember
Chapter

Abstract

(A) Treatment for hypogonadism (HG) is indicated in men with laboratory evidence of testosterone (T) deficiency who have clinically significant signs or symptoms, and in whom contraindications to treatment (Table 12.1) are not present.

Keywords

Luteinizing Hormone Benign Prostatic Hyperplasia Aromatase Inhibitor Clomiphene Citrate Luteinizing Hormone Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Reading

  1. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2539–59.CrossRefGoogle Scholar
  2. Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med. 2011;8(3):639–54.PubMedCrossRefGoogle Scholar
  3. Cunningham GR, Toma SM. Clinical review: why is androgen replacement in males controversial? J Clin Endocrinol Metab. 2011;96(1):38–52.PubMedCrossRefGoogle Scholar
  4. Hsiao W, Tenover JS, Ritenour C. The role of Testosterone Replacement Therapy in Contemporary Urological Practice. American Urological Association Update Series. 2008.Google Scholar
  5. Katz DJ, Nabulsi O, Tal O, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int. 2012;110(4):573–8. doi: 10.1111/j.1464-410X.2011.10702.x.PubMedCrossRefGoogle Scholar
  6. Moskovic DJ, Katz DJ, Akhavan A, Park K, Mulhall JP. Clomiphene citrate is safe and effective for long-term management of hypogonadism. BJU Int. 2012;110(10):1524–8. doi: 10.1111/j.1464-410X.2012.10968.x.PubMedCrossRefGoogle Scholar
  7. Practice Committee of American Society for Reproductive Medicine in collaboration with Society for Male Reproduction and Urology. Androgen deficiency in the aging male. Fertil Steril. 2008;90(5 Suppl):S83–7.Google Scholar
  8. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Eng J Med. 2004;350:482–92.CrossRefGoogle Scholar
  9. Sokol RZ. Endocrinology of male infertility: evaluation and treatment. Semin Reprod Med. 2009;27(2):149–58.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • John P. Mulhall
    • 1
  • Peter J. Stahl
    • 2
  • Doron S. Stember
    • 3
  1. 1.Sexual and Reprodictive Medicine Program Department of Surgery Division of Urology, Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of UrologyColumbia University College of Physicians & SurgeonsNew YorkUSA
  3. 3.Department of UrologyBeth Israel Medical Center Albert Einstein College of Medicine of Yeshiva UniversityNew YorkUSA

Personalised recommendations